524322 KABRADG

Kabra Drugs Share Price

₹10.06 0.00 (0.00%)

29 Dec, 2024 07:08

SIP TrendupStart SIP in KABRADG

Start SIP

Performance

  • Low
  • ₹0
  • High
  • ₹0
  • 52 Week Low
  • ₹0
  • 52 Week High
  • ₹0
  • Open Price₹0
  • Previous Close₹0
  • Volume0

Investment Returns

  • Over 1 Month + 4.9%
  • Over 3 Month + 10.07%
  • Over 6 Month + 27.18%
  • Over 1 Year + 86.64%
SIP Lightning

Smart Investing Starts Here Start SIP with Kabra Drugs for Steady Growth!

Invest Now

Kabra Drugs Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

Kabra Drugs Financials

Kabra Drugs Technicals

EMA & SMA

Current Price
₹10.06
0 (0%)
pointer
  • stock-down_img
  • Bullish Moving Average 16
  • stock-up_img
  • Bearish Moving Average 0
  • 20 Day
  • ₹9.17
  • 50 Day
  • ₹8.01
  • 100 Day
  • ₹6.86
  • 200 Day
  • ₹5.77

Resistance and Support

10.06 Pivot Speed
  • R3 10.06
  • R2 10.06
  • R1 10.06
  • S1 10.06
  • S2 10.06
  • S3 10.06

What's your outlook on Kabra Drugs?

You can only vote for once

Kabra Drugs Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2024-11-14 Quarterly Results
2024-11-04 Others
2024-08-14 Quarterly Results
2024-07-12 Others Inter alia, 1. To consider and change the registered office of the Company within the local limits of city where the registered office of the company is presently situated;
2024-05-30 Audited Results

Kabra Drugs F&O

Kabra Drugs Shareholding Pattern

No data available.

About Kabra Drugs

  • NSE Symbol
  • KABRADG
  • BSE Symbol
  • 524322
  • ISIN
  • INE323K01017

Similar Stocks to Kabra Drugs

Kabra Drugs FAQs

Kabra Drugs share price is ₹10 As on 29 December, 2024 | 06:54

The Market Cap of Kabra Drugs is ₹10.1 Cr As on 29 December, 2024 | 06:54

The P/E ratio of Kabra Drugs is -7.1 As on 29 December, 2024 | 06:54

The PB ratio of Kabra Drugs is -6.9 As on 29 December, 2024 | 06:54

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23